Arca
Skip to content

Osteoporosis

Drug research and approvals for osteoporosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 120 studies of osteoporosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 1 approved and 1 open orphan designations naming it, and the EU has 35 authorised medicines for it.

  • Recruiting worldwide: 120
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 1
  • EU medicines: 35

Recruiting Now

Newest start dates first, of 120 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
May 16, 2022Efficacy of a single infusion of zoledronic acid to mitigate the rebound effect of rapid bone loss following denosumab treatment discontinuationZOLEDRONIC ACIDGOVERNORS OF THE UNIVERSITY OF CALGARYPending
Mar 6, 2019A randomized, double-blind, placebo-controlled, phase 3 multicenter study to evaluate the safety and efficacy of abaloparatide-sc for the treatment of men with…ABALOPARATIDE (BA058)Radius HealthClosed
Jul 21, 2017A phase 3 randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of denosumab in pediatric subjects with…PROLIAAmgenOngoing
Jun 7, 2017The efficacy and safety of rosuvastatin for modifying bone mass and cardiometabolic disease outcomes (robaco trial)ROSUVASTATINDR BEVERLY CATHARINE CRAVENOngoing
Jan 7, 2016A single-blinded, randomized, controlled, phase 2 pilot study to evaluate the safety and efficacy of denosumab compared to zoledronic acid for the treatment of…PROLIA / ZOLEDRONIC ACIDCHILDRENS HOSPITAL OF EASTERN ONTARIOClosed
May 14, 2014Risedronate in chronic kidney disease (rick): a randomized controlled pilot studyRISEDRONATEWOMENS COLLEGE HOSPITALPending
Feb 5, 2014A multicenter, double-blind, randomized study to assess the efficacy and safety of denosumab produced by two different processess in postmenopausal women with…PROLIA (DENOSUMAB)AmgenPending

FDA Orphan Designations

Approved first, then open designations, newest first
Sep 13, 2007EvistaReduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in…Eli Lilly and CompanyApproved
Oct 28, 1999TeriparatideTreatment of idiopathic osteoporosis.Biomeasure, Inc.Designated

Medicines Authorised in the EU

Newest first; 15 of 35
Apr 27, 2026Zandoriahteriparatide · biosimilarCinnaGen Co Unipessoal LDAEMA ↗
Jan 8, 2026Osqaydenosumab · biosimilarTheramex Ireland LimitedEMA ↗
Nov 17, 2025Kefdensisdenosumab · biosimilarStada Arzneimittel AGEMA ↗
Nov 17, 2025Acvybradenosumab · biosimilarReddy Holding GmbHEMA ↗
Nov 17, 2025Vysribli (previously Denosumab Intas)Vysribli · biosimilarIntas Third Party Sales 2005 S.L.EMA ↗
Nov 17, 2025Ponlimsidenosumab · biosimilarTeva GmbHEMA ↗
Sep 17, 2025Bildyosdenosumab · biosimilarSciencepharma Sp. z o.oEMA ↗
Jul 18, 2025Conexxencedenosumab · biosimilarFresenius Kabi Deutschland GmbHEMA ↗
Jul 17, 2025Rolcyadenosumab · biosimilarSandoz GmbHEMA ↗
Jun 30, 2025Evfraxydenosumab · biosimilarBiosimilar Collaborations Ireland LimitedEMA ↗
Jun 26, 2025Zadenvidenosumab · biosimilarZentiva k.s.EMA ↗
Jun 26, 2025Izambydenosumab · biosimilarMabxience Research SLEMA ↗
Jun 23, 2025Junoddenosumab · biosimilarGedeon Richter Plc.EMA ↗
May 26, 2025Osvyrtidenosumab · biosimilarAccord Healthcare S.L.U.EMA ↗
Feb 14, 2025Stoboclodenosumab · biosimilarCelltrion Healthcare Hungary Kft.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.